Samsung and SK Hynix shares dropped on Monday after the U.S. made it harder for South Korea to produce semiconductor equipment in China.Samsung and SK Hynix shares dropped on Monday after the U.S. made it harder for South Korea to produce semiconductor equipment in China.

Samsung and SK Hynix tumble after U.S. tightens chip export rules

Samsung Electronics and SK Hynix shares plummeted on Monday in the wake of revised rulings on critical semiconductor shipping requirements from the U.S. The new ruling also makes it harder for the world’s largest memory chipmakers to ship their equipment to their giant Chinese operations. 

At the time of publication, Samsung shares slid more than 3% in the last 24 hours to 67,600 KRW. SK Hynix shares also dropped nearly 5% during the same period to 256,250 KRW.

U.S. ruling impacts sales of semiconductor equipment to China

The Department of Commerce’s Bureau of Industry and Security said it does not intend to grant licenses to expand capacity or upgrade technology at fabs in China. Both Samsung and SK Hynix have several memory plants in Korea, while Beijing also accounts for a major slice of both Korean companies’ global output. 

Samsung manufactures nearly 40% of its total NAND flash memory chips at its production plant in Xi’an, Shaanxi. SK Hynix also produces 20% of its NAND flash chips in Dalian, Liaoning, and roughly 40% of its DRAM in Wuxi, Jiangsu.

In 2023, the former-President Biden’s administration granted the duo the ability to operate in China under regulations allowing them to import semiconductor equipment without applying for a new license. The Trump administration seeks to overturn what’s known as the validated end user (VEU) rules. 

The Commerce Department said on Friday that the companies will now need to obtain licenses to export their technology to China, but will not be granted licenses to expand capacity or upgrade technology. As recently reported by Cryptopolitan, both firms have 120 days until the waiver expires.

Samsung Executive Chairman Jay Lee was also asked on Sunday about the impact of the new ruling on its Chinese business and argued that the company will have to work hard. South Korea’s government said the stability of the global semiconductor supply chain depends on the stable operation of its semiconductor companies in Beijing. The government also promised to continue discussions with the U.S. to mitigate the impact on South Korean Companies.

A spokesperson for Beijing’s commerce ministry said China opposes the new U.S. ruling. The agency also said it will take necessary measures to resolutely safeguard the legitimate rights and interests of its enterprises.

U.S. ruling comes amid heightened U.S. trade policies

The new U.S. measures came amid heightened U.S. trade policies that have disrupted global trade for the better part of the year. The U.S. Commerce Department hinted in June at the possibility of revoking the rules, after a White House official said the U.S. was preparing in case the truce in trade talks with South Korea fell apart.

The U.S. and South Korea agreed on a 15% levy on Seoul imports to the U.S. from August 7. China and the U.S. also agreed on 30% tariffs on Chinese imports to the U.S. and 10% levies on U.S. goods till November. As previously reported by Cryptopolitan, the country’s trade minister, Yeo Han-koo, also said both Samsung and SK Hynix are exempted from 100% U.S. levies on semiconductor equipment.

Chris Miller, the author of ‘Chip War,’ argued that the U.S. measures will make it harder for Korean chipmakers with facilities in China to continue producing more advanced chips. He also believes that the move risks opening market space for Chinese firms at the expense of the Korean firms if the measure isn’t accompanied by further steps against Chinese chipmakers.

Want your project in front of crypto’s top minds? Feature it in our next industry report, where data meets impact.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26